We have developed a miniaturized semiclosed cardiopulmonary bypass (CPB) circuit incorporating a centrifugal blood pump (TinyPump) with a volume of 5 ml. The current study was undertaken to evaluate the hemolytic performance of the TinyPump in comparison with the BioPump and to investigate the impact of different CPB circuit volumes on hemodilution, coagulation, and the inflammatory response. Twelve 1-weekold piglets (3.4 ؎ 0.2 kg) were used. The circuit comprised a centrifugal pump, a membrane oxygenator, and a cardiotomy reservoir. Cardiopulmonary bypass was conducted with mild hypothermia at 150 ml/kg/min for 3 hours. Transfusion was not performed. Priming volume was 68 ml for the circuit with the TinyPump and 111 ml for the circuit with the BioPump. Although the TinyPump required higher speed, plasma free hemoglobin levels after CPB were not different between the groups. After CPB, the TinyPump group had a significantly higher hematocrit (27% ؎ 3% vs. 23% ؎ 3%) and lower platelet reduction rate, lower thrombin-antithrombin complex levels, and lower interleukin-6 levels. Better lung compliance with less water content was observed in the Tiny-Pump group. The TinyPump maintained CPB with acceptable hemolysis and lower inflammatory responses. This miniaturized CPB circuit may make transfusion-free open heart surgery feasible in neonates and would help to prevent postoperative organ dysfunction. ASAIO Journal 2007; 53:675-679.
Asanguineous priming of cardiopulmonary bypass (CPB) circuits is a prerequisite for accomplishing transfusion-free open heart surgery, but inevitable hemodilution reduces colloid osmotic pressure, lowers hematocrit, and decreases the concentration of coagulation factors. 1 Although the transfusionfree strategy is not clinically practical yet in neonates, these deleterious effects of hemodilution are more pronounced in neonates than in older pediatric or adult patients, because of their immature tissue and organ function in the first few months of life. To diminish not only hemodilution but also the area for blood-synthetic surface interactions in pediatric patients, miniaturization of CPB circuits has been attempted using innovative techniques such as the application of retrograde autologous priming, 2 reduction of suction lines, 3 and downsizing venous cannulae with a vacuum or kinetic-assisted drainage system. 4 We have recently developed a seal-less, ultraminiature rotary centrifugal blood pump (TinyPump) with a priming volume of 5 ml (Figure 1) . The pump incorporates an impeller with six straight vanes, supported by a hydrodynamic bearing at its center and rotated with a radial-coupled magnetic driver. The blood contacting surface of this pump was coated with a biocompatible 2-methacryloyloxyethyl phosphorylcholine (MPC) polymer. 5 Our previous study demonstrated that pump flow through an oxygenator and a 2.6 mm arterial cannula was 0.76 L/min at a rotational speed of 4,385 rpm with the pressure drop of 250 mm Hg in a mock circulatory loop, and that pump flow of 1.5 L/min was secured for CPB with a 4.0 mm arterial cannula in 20 kg piglets. 6 To reduce the priming volume of the CPB circuit as much as possible, we devised miniature semiclosed CPB systems incorporating the TinyPump or a BioPump (BP-50, Medtronic, Minneapolis, MN) and performed CPB in neonatal piglets without transfusion. The current study was undertaken to evaluate hemolytic performance of the TinyPump for CPB in comparison with the BioPump and to investigate the impact of different priming volumes of the CPB circuit on hemodilution, coagulation, and inflammatory responses.
Materials and Methods

Animal Preparation
All experimental animals were cared for in accordance with institutional guidelines and the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Science and published by the National Institutes of Health (NIH Publication 86-23, revised 1985). The experimental protocol was approved by the Okayama University School of Medicine Experimental Animals Committee. Twelve 1-weekold piglets with a mean body weight of 3.4 Ϯ 0.2 kg were used for the experiments. Methylprednisolone (30 mg/kg) was administered 2 hours before surgery. Animals were premedicated with intramuscular ketamine hydrochloride (20 mg/kg) and acepromazine (1 mg/kg). After induction of anesthesia with pentobarbital (25 mg/kg) and pancuronium (0.2 mg/kg), the animals were mechanically ventilated with a tidal volume of 10 ml/kg and a peak end-expiratory pressure of 5 cm H 2 O. Isoflurane inhalation (1%-2%) and intermittent infusion of pentobarbital (10 mg/kg) were used to maintain anesthesia. Ventilator settings were adjusted to maintain an arterial PCO 2 of 35-45 mm Hg. Rectal temperature was continuously monitored. Catheters (22 gauge) were placed in the left carotid artery and in the left internal jugular vein for pressure monitoring and blood gas sampling. The heart was exposed through a median sternotomy. A micromanometer was inserted into the left atrium for pressure monitoring. A 5F Swan-Ganz catheter (Arrow, PA) was inserted into the main pulmonary artery.
Miniaturized Circuit
The miniaturized circuit comprised either the TinyPump (n ϭ 6) or the BioPump (n ϭ 6), a membrane oxygenator (Capiox RX 05, Terumo, Japan), a hard-shell cardiotomy reservoir, a 2.6 mm aortic cannula (Stö ckert, Sorin, Germany) and a 14F venous cannula (DLP, Medtronic). Both arterial perfusion and the venous drainage lines were 3/16 inch in internal diameter and 50 cm in length respectively, and the line between the centrifugal pump and the oxygenator was 1/4 inch in internal diameter and 10 cm in length. The inner surface of the tubing line was not coated with biocompatible materials. A flow probe (Transonic System, Inc., Ithaca, NY) was placed on the perfusion line. The same circuit was used in both groups. As for driving mechanism, the impeller-rotor of the TinyPump is supported by a hydrodynamic bearing at its center and rotated by radial magnetic induction force between the follower magnets inside the impeller and the driver magnets mounted on the motor shaft outside the pump head, whereas the cone-rotor of the BioPump is supported by a blood-immersed mechanical bearing at its bottom and rotated by axial magnetic induction force between the follower magnets inside the cone-rotor and the driver magnets mounted on the motor shaft outside the pump head.
Cardiopulmonary Bypass
The circuit was primed with 25% albumin (20 ml), sodium bicarbonate (2 ml/kg), mannitol (2 ml/kg), methylprednisolone (30 mg/kg), and lactated Ringer's solution. Anticoagulation was induced with heparin sodium (300 U/kg) to maintain activated clotting time greater than 480 seconds. Cardiopulmonary bypass was established by cannulation to the aortic root (Stö ckert, 2.6 mm, Sorin, Germany) and to the right atrium (DLP, 14F, Medtronic). Venous blood was drained kinetically by the centrifugal pump. During CPB, the lungs were ventilated once every minute keeping an end-expiratory pressure of 5 cm H 2 O. Cardiopulmonary bypass was conducted with mild hypothermia (30°C-32°C) at a flow rate of 150 ml/kg/min for 3 hours. The heart was not arrested in this study. If an additional volume was required, lactated Ringer's solution was added to the circuit. At the end of each experiment, the animal was killed by intravenous injection of potassium chloride.
Hemodynamics
Hemodynamic variables, including heart rate, mean arterial pressure, mean pulmonary artery pressure, central venous pressure, and left atrial pressure were continuously monitored. Ten minutes before and 10 minutes after CPB, cardiac output was measured by the thermodilution technique, and airway pressure was assessed to calculate static pulmonary compliance. Both cardiac output and pulmonary vascular resistance were indexed by dividing by the animal's weight.
Blood Sampling
Blood samples were serially collected 10 minutes before CPB, 90 minutes after the initiation of CPB, and 10 minutes after its termination. The parameters measured in this study were complete blood cell counts, plasma total proteins, plasma free hemoglobin levels, thrombin-antithrombin complex (TAT) levels, and interleukin-6 (IL-6) levels. Platelet reduction rate was calculated by using the following equation:
The samples were centrifuged for 10 min, and the serum was stored at Ϫ70°C. Plasma free hemoglobin levels were measured by spectrophotometry. Thrombin-antithrombin complex levels were measured using an enzyme immunoassay kit (SRL, Tokyo, Japan). Interleukin-6 values were determined using an enzyme-linked immunosorbent assay kit (R&D Systems, Minneapolis, MN).
Heart and Lung Water Gain
The free wall of the left ventricle and a peripheral lung specimen were obtained immediately after death, and were weighed, desiccated in a warming oven at 80°C for 24 hours, and then reweighed to determine the water content.
Statistical Analysis
All data were expressed as means Ϯ standard deviations. The Mann-Whitney test was used to compare differences between the groups. The Wilcoxon's signed-rank test was used for intragroup comparisons. A p value less than 0.05 was considered statistically significant.
Results
The priming volume of the semiclosed circuit incorporating the TinyPump was 68 ml, whereas this value was 111 ml for the BioPump. All animals were weaned from CPB without inotropic support. Both pumps maintained perfusion flow at around 500 ml/min. Although the TinyPump required higher pump speed (3,508 Ϯ 166 vs. 2,005 Ϯ 55 rpm, p Ͻ 0.05), plasma free hemoglobin levels after CPB were not different between the groups (13.3 Ϯ 6.86 vs. 11.5 Ϯ 3.02 mg/dl, Figure  2) . No pump-related problems arose, and a visual inspection confirmed no thrombus formation inside the pump in any experiment.
Hemodynamic Profile and Blood Gas Analyses
In both groups, heart rate tended to increase and mean arterial pressure tended to decrease, but only mean pulmonary artery pressures were significantly elevated after CPB ( Table 1 ). Blood gas analyses showed constant pH levels at 7.30 -7.40. PaO 2 and SvO 2 in the BioPump group were decreased after the end of CPB, but they were not significantly different between the groups ( Table 2) .
Cardiopulmonary Function and Water Content
There was no difference in cardiac index before and after CPB in either group. Myocardial water content after the experiment also did not differ between the groups. Pulmonary vascular resistance increased after CPB in both groups, but, again, did not differ between them. In the BioPump group, static pulmonary compliance decreased after CPB, and lung water content was higher than in the TinyPump group ( Table 3) .
Hematocrit and Plasma Protein
The hematocrit dropped after the initiation of CPB in both groups, but the TinyPump group maintained higher levels than the BioPump group at 90 minutes during CPB (27% Ϯ 2% vs. 22% Ϯ 2%, p Ͻ 0.05) and after CPB (27% Ϯ 3% vs. 23% Ϯ 3%, p Ͻ 0.05) (Figure 3) . Similarly, plasma total protein level after CPB in the TinyPump group was higher than in the BioPump group (4.1 Ϯ 0.8 vs. 3.0 Ϯ 0.4 g/dl, p Ͻ 0.05), although plasma total protein significantly decreased from the baseline value in both groups (5.6 Ϯ 0.5 vs. 5.4 Ϯ 0.6 g/dl).
Platelet Counts, TAT, and IL-6
Platelet counts decreased during CPB in both groups (Figure  4) , but the TinyPump group had higher platelet counts and lower platelet reductions than the BioPump group after CPB (1.09 Ϯ 0.29 vs. 1.62 Ϯ 0.38, p Ͻ 0.05). In contrast, TAT levels increased during CPB in both groups, but the TinyPump group had lower TAT levels than the BioPump group after CPB. In both groups, no IL-6 was detectable before CPB (less than 39.1 pg/ml) but markedly increased during CPB. Interleukin-6 levels after CPB in the BioPump group exceeded the maximum measurable concentration (greater than 5,000 pg/ml) in all animals ( Table 4 ).
Discussion
Despite successful surgical repair of congenital heart defects in neonates, limitations in outcome are sometimes encountered in relation to exposure to CPB. 7 The deleterious effects of CPB in neonates are often pronounced because of their immature tissue and organ function and disparity between the CPB circuit and the patient's size. Some surgeons have recently succeeded in performing transfusion-free open heart surgery in Jehovah's witness patients weighing less than 5 kg by using a low prime CPB circuit and aggressive blood conservation techniques. 8, 9 However, there has been little progress in developing CPB systems specifically for this population. As a first step towards transfusion-free neonatal open heart surgery, we have designed miniature CPB circuits incorporating the TinyPump. Our results demonstrated that the TinyPump maintains CPB at around 500 ml/min with acceptable hemolysis in the neonatal piglet model, and that miniaturization of the CPB circuit may contribute to the preservation of hematocrit and plasma protein levels as a result of less hemodilution. Additional benefits also included lower inflammatory responses and less platelet reduction because of a smaller area available for blood-synthetic surface interactions.
The CPB-induced inflammatory response is usually attributed to exposure of blood to synthetic surfaces, resulting in the release of pro-inflammatory cytokines. One of these, IL-6, is a pleiotropic cytokine inducible in many human tissues, including bronchial epithelial cells and alveolar macrophages. 10 IL-6 mediates the "acute phase response" by stimulating the proliferation of neutrophil progenitors and by sensitizing neutrophils to the effects of subsequent inflammatory mediators. Increased serum IL-6 levels are associated with the capillary leak syndrome in patients with severe infection. 11 Hauser et al. 12 documented a correlation of increased serum IL-6 levels with postoperative morbidity and mortality in children undergoing open heart surgery. In addition, increases in IL-6 levels after CPB are more pronounced in neonates than in infants. 13 Bical et al. 14 found increased IL-6 levels in all adult patients undergoing aortic valve surgery but no difference in IL-6 level between miniaturized CPB and standard CPB. In the current study, the TinyPump group had lower post-CPB IL-6 levels than the BioPump group. A smaller blood contacting surface area of the TinyPump may contribute to preventing activation of inflammatory pathways. Platelet activation is caused by contact with the CPB circuit and is closely regulated by endothelial cell activation in response to inflammation, especially in the form of thrombin. 15 This results in the widespread consumption of coagulation factors. Additionally, platelets are removed from the circulation secondary to adherence to the CPB circuit. The TinyPump group had lower TAT levels and platelet reduction rates after CPB, indicating less thrombin formation and platelet consumption. The lower blood contacting surface area of the circuit and resultant reduced inflammatory response might contribute to these results. Furthermore, the MPC polymer, which was used to coat the inner surface of the TinyPump, was reported to reduce thrombin formation. 16 Given the immaturity of the coagulation system in neonates, which poses potential risks of postoperative bleeding, this benefit is of particular importance to reduce postoperative coagulopathy-related morbidity and blood transfusion requirements in neonatal open heart surgery.
Cardiopulmonary bypass leads to various degrees of pulmonary dysfunction, which is manifested by decreased pulmonary compliance and poor alveolar gas exchange. 7, 17 Hemodilution results in reduced colloid oncotic and capillary filtration pressures. Inflammatory mediators induced by CPB, such as tumor necrosis factor-␣ and interleukins, accentuate neutrophil-mediated lung injury. In this study, the TinyPump group maintained better pulmonary compliance and experienced less pulmonary edema. Thus, these consequences would be associated with less hemodilution and lower inflammatory responses.
This study has certain limitations. First, the ability of the TinyPump to maintain CPB was evaluated for only 3 hours. Second, we did not perform ultrafiltration during CPB, which removes chemical mediators from circulating blood. Finally, some ancillary equipment such as an arterial filter and cardioplegia circuit were eliminated to simplify the circuit. Therefore, this small priming volume of 68 ml and the results in this study cannot be directly translated to clinical practice.
Conclusion
The TinyPump placed in the miniature semiclosed circuit maintained circulation with acceptable hemolysis in the neo-natal piglet model. This system minimized hemodilution and attenuated the systemic inflammatory response, thereby better preserving the integrity of the coagulation system and pulmonary function. Although the safe lowest limit of the hematocrit during CPB at any temperature is as yet undetermined, we believe that this miniaturized CPB circuit could make transfusion-free neonatal open heart surgery feasible.
